Germany's BioNTech to buy CureVac to boost cancer research / Photo: ANDRE PAIN - AFP
-
Stocks mixed and oil rises as US, Iran call end to latest attacks
-
EU, China trade tensions loom over minister visit
-
For sale on Facebook: monkeys, rhino horn and dead pangolins
-
Israelis, Palestinians torn over sacred shrine in city of Hebron
-
In Sudan's Kordofan, a key city reels as paramilitary offensive looms
-
Scheffler to face Hovland in Monday playoff for PGA Travelers title
-
Ryu Hae-ran wins Women's PGA Championship
-
'Burnt out' Stokes leaves England facing tricky questions
-
Germany must win to defy World Cup doubters, says Nagelsmann
-
Critical rescue window closing in Venezuela as quake death toll nears 1,500
-
South Korea's Ryu Hae-ran wins Women's PGA Championship
-
Canada's Marsch praises history-making World Cup 'heroes'
-
Brazil strike confident tone ahead of Japan World Cup clash
-
Co-hosts Canada beat South Africa to reach World Cup last 16 as knockouts begin
-
Israel detonates tunnel, strikes south Lebanon
-
Putin acknowledges fuel shortages after Ukraine strikes
-
Moriyasu praises 'united' Japan on eve of Brazil World Cup clash
-
Canada reach World Cup last 16 as late strike sinks South Africa
-
Looting, theft in Venezuela's earthquake zone add to tragedy
-
Perry stars as Australia knock India out of World Cup
-
Venezuela quakes kill 1,450, time running out to find survivors
-
Stokes 'content' after extraordinary England exit
-
West Indies beat Sri Lanka in first Test
-
Europe swelters as heatwave moves east
-
Asia's World Cup falls apart with just two teams remaining
-
Stokes announces shock England exit as New Zealand eye series win
-
Bromell upsets Lyles, Duplantis shines at Paris Diamond League
-
CAF president Motsepe hails African World Cup successes
-
Man Utd reveal Ugarte knee injury in Uruguay World Cup defeat
-
South Korea coach quits after early World Cup exit
-
Stokes out for 30 in final Test innings after shock England retirement
-
Venezuela quakes kill 1,400, time running out to find survivors
-
Wolff praises 'cold-blooded' Russell, enjoys Antonelli enthusiasm at Austrian GP
-
Hamilton laments lack of power and poor tyre performance
-
Stokes announces shock England exit as Mitchell bats New Zealand into commanding lead
-
Goals galore at record-breaking World Cup
-
Russell overcomes 'tricky run of form' to revive title bid
-
Augusta Tops Best Gold IRA Companies List By Gold Advisor
-
Europe swelters as heatwave moves east, excess deaths rise
-
They support Argentina at the World Cup, but are not Argentine
-
Raducanu hopes to feature at Wimbledon despite injury woe
-
Iran warns ships not to bypass its chosen Hormuz route
-
Russell holds off Verstappen to win Austrian Grand Prix
-
Serena blasts drug test rules ahead of Wimbledon return
-
England captain Stokes to retire from international cricket
-
Ogier wins Acropolis Rally to close in on Evans
-
South Africa maintain World Cup semi-final hopes with nervy win over Bangladesh
-
South Korea president apologises after World Cup group-stage exit
-
Japan's Ogura wins maiden MotoGP as Bezzecchi crashes in Assen
-
Bergs wins Eastbourne final to clinch first ATP title
Germany's BioNTech to buy CureVac to boost cancer research
Germany's BioNTech is buying domestic rival CureVac for $1.25 billion, the companies said Thursday, bringing together two pharmaceutical firms specialised in mRNA technology with the goal of advancing cancer treatments.
BioNTech, which developed the first coronavirus vaccine to be approved in the West along with US pharmaceutical giant Pfizer, said the acquisition would "bring together complementary capabilities and leverage technologies".
Both biotech companies have been working for years in the area of mRNA vaccines and treatments, which provoke an immune response by delivering genetic molecules containing the code for key parts of a pathogen into human cells.
While the technology became well known in relation to some Covid-19 vaccines, it is also being used in other areas, and scientists believe it could be a game-changer against many diseases.
BioNTech said the acquisition of CureVac would help boost its work in the field of mRNA-based cancer immunotherapy -- treatment that uses the body's own immune system to fight diseases.
"This transaction is another building block in BioNTech's oncology strategy and an investment in the future of cancer medicine," said BioNTech CEO Ugur Sahin.
It was aimed at "establishing new standards of care for various types of cancer in the coming years," he said.
Alexander Zehnder, CEO of CureVac, said the purchase would bring scientific expertise, technology and manufacturing know-how "in the mRNA field under one roof".
BioNTech's all-stock acquisition has been unanimously approved by the companies' management and supervisory boards, and is expected to close in 2025, subject to certain conditions including regulatory approvals.
Both companies are listed on the Nasdaq Composite Index.
They had both sought to develop Covid-19 vaccines during the pandemic, with Mainz-based BioNTech's Comirnaty jab winning approval and going on to become one of the most widely used shots against the virus around the world.
But Tuebingen-based CureVac, founded 25 years ago by mRNA pioneer Ingmar Hoerr, abandoned its efforts in late 2021 after disappointing trial results.
In 2022, CureVac sued BioNTech for patent infringement over its rival's use of the technology.
N.Mitchell--AT